The US Supreme Court has agreed to review Matrixx Initiatives Inc v Siracusano, a case that has the potential to determine which adverse event reports a drug maker must disclose to shareholders to avoid securities suits1.
Specifically, the case addresses the question of whether Matrixx, a company marketing the homeopathic intranasal cold therapy Zicam (zinc gluconate), had a duty to publicly disclose adverse drug event reports to shareholders even though the events were not statistically significant...
Please login to read the full article.